<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36107978</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Identification of quantitative trait loci for survival in the mutant dynactin p150Glued mouse model of motor neuron disease.</ArticleTitle><Pagination><StartPage>e0274615</StartPage><MedlinePgn>e0274615</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0274615</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0274615</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common degenerative motor neuron disorder. Although most cases of ALS are sporadic, 5-10% of cases are familial, with mutations associated with over 40 genes. There is variation of ALS symptoms within families carrying the same mutation; the disease may develop in one sibling and not in another despite the presence of the mutation in both. Although the cause of this phenotypic variation is unknown, it is likely related to genetic modifiers of disease expression. The identification of ALS causing genes has led to the development of transgenic mouse models of motor neuron disease. Similar to families with familial ALS, there are background-dependent differences in disease phenotype in transgenic mouse models of ALS suggesting that, as in human ALS, differences in phenotype may be ascribed to genetic modifiers. These genetic modifiers may not cause ALS rather their expression either exacerbates or ameliorates the effect of the mutant ALS causing genes. We have reported that in both the G93A-hSOD1 and G59S-hDCTN1 mouse models, SJL mice demonstrated a more severe phenotype than C57BL6 mice. From reciprocal intercrosses between G93A-hSOD1 transgenic mice on SJL and C57BL6 strains, we identified a major quantitative trait locus (QTL) on mouse chromosome 17 that results in a significant shift in lifespan. In this study we generated reciprocal intercrosses between transgenic G59S-hDCTN1 mice on SJL and C57BL6 strains and identified survival QTLs on mouse chromosomes 17 and 18. The chromosome 17 survival QTL on G93A-hSOD1 and G59S-hDCTN1 mice partly overlap, suggesting that the genetic modifiers located in this region may be shared by these two ALS models despite the fact that motor neuron degeneration is caused by mutations in different proteins. The overlapping region contains eighty-seven genes with non-synonymous variations predicted to be deleterious and/or damaging. Two genes in this segment, NOTCH3 and Safb/SAFB1, have been associated with motor neuron disease. The identification of genetic modifiers of motor neuron disease, especially those modifiers that are shared by SOD1 and dynactin-1 transgenic mice, may result in the identification of novel targets for therapies that can alter the course of this devastating illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Guillermo M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-5236-2391</Identifier><AffiliationInfo><Affiliation>Temple MDA/ALS Center of Hope, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry D</ForeName><Initials>TD</Initials><Identifier Source="ORCID">0000-0002-9910-1041</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Lewis Katz School of Medicine of Temple University, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bearoff</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1344-8168</Identifier><AffiliationInfo><Affiliation>Department of Microbiology Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sher</LastName><ForeName>Roger B</ForeName><Initials>RB</Initials><Identifier Source="ORCID">0000-0003-3327-537X</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennessy</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terek</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caccavo</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Lewis Katz School of Medicine of Temple University, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philip</LastName><ForeName>Vivek M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blankenhorn</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Microbiology Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS102414</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072159">Dynactin Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072159" MajorTopicYN="N">Dynactin Complex</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>13</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36107978</ArticleId><ArticleId IdType="pmc">PMC9477371</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0274615</ArticleId><ArticleId IdType="pii">PONE-D-22-12603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen PM and Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603&#x2013;615. doi: 10.1038/nrneurol.2011.150</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupr&#xe9; N, Petri S, Strong M, Kriz J, et al.. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429&#x2013;2447. doi: 10.1084/jem.20111313</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Kwak Sm Mehler M. et al.: Genetic and epigenetic studies of amyotrophic lateral sclerosis Amyotrophic lateral sclerosis and fronto temporal degeneration. 2013; Suppl 1:44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23678879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Fagegaltier D, Phatnani H and Harms MB. Genetics of Amyotrophic Lateral Sclerosis. Current Genetic Medicine Reports. 2020;8:121&#x2013;131.</Citation></Reference><Reference><Citation>Siddique T, Figlewicz DA, Pericak-Vance MA, Haines JL, Rouleau G, Jeffers AJ, et al.. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med. 1991;324(20):1381&#x2013;1384. doi: 10.1056/NEJM199105163242001</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199105163242001</ArticleId><ArticleId IdType="pubmed">2020294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al.. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature.1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al.. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BM, Gordon JW, Ripps ME, Morrison JH. Quantitative immunocytochemical analysis of the spinal cord in G86R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol 1996;373(4):619&#x2013;631. doi: 10.1002/(SICI)1096-9861(19960930)373:4&amp;lt;619::AID-CNE9&amp;gt;3.0.CO;2-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(19960930)373:4&amp;lt;619::AID-CNE9&amp;gt;3.0.CO;2-4</ArticleId><ArticleId IdType="pubmed">8889947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994;145:1271&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887498</ArticleId><ArticleId IdType="pubmed">7992831</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC and Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 1995;676:25&#x2013;40. doi: 10.1016/0006-8993(95)00063-v</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(95)00063-v</ArticleId><ArticleId IdType="pubmed">7796176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC and Gurney ME. A low expressor line of transgenic mice carrying a mutant human Cu, Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol. 1997;93(6):537&#x2013;550. doi: 10.1007/s004010050650</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050650</ArticleId><ArticleId IdType="pubmed">9194892</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, et al.. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci. 2005; 236(1&#x2013;2):1&#x2013;7. doi: 10.1016/j.jns.2005.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Sher RB, Blankenhorn EP, Alexander G, Deitch JS, Kunst CB, et al.. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler. 2011;12(2):79&#x2013;86. doi: 10.3109/17482968.2010.550626</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.550626</ArticleId><ArticleId IdType="pubmed">21241159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sher RB, Heiman-Patterson TD, Blankenhorn EA, Jiang J, Alexander G, Deitch JS, et al.. A major QTL on mouse chromosome 17 resulting in lifespan variability in SOD1-G93A transgenic mouse models of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2014;15(7&#x2013;8):588&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">25008789</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al.. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33(4):455&#x2013;456. doi: 10.1038/ng1123</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1123</ArticleId><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, Oh SJ, Sumner CJ, Wallace KE, Floeter MK, Mann EA, et al.. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol. 2005;57(5):687&#x2013;694. doi: 10.1002/ana.20468</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20468</ArticleId><ArticleId IdType="pmc">PMC1351270</ArticleId><ArticleId IdType="pubmed">15852399</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Farah MH, Ackerley S, Hoke A, Maragakis N, Rothstein JD, et al.. Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci. 2008;28(9):1997&#x2013;2005. doi: 10.1523/JNEUROSCI.4231-07.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4231-07.2008</ArticleId><ArticleId IdType="pmc">PMC6671836</ArticleId><ArticleId IdType="pubmed">18305234</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Blankenhorn EP, Sher RB, Jiang J, Welsh P, Dixon MC, et al.. Genetic background effects on disease onset and lifespan of the mutant dynactin p150Glued mouse model of motor neuron disease. PLoS One. 2015;10(3):e0117848. doi: 10.1371/journal.pone.0117848</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0117848</ArticleId><ArticleId IdType="pmc">PMC4357475</ArticleId><ArticleId IdType="pubmed">25763819</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, et al.. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004;130(1&#x2013;2):7&#x2013;15. doi: 10.1016/j.molbrainres.2004.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbrainres.2004.07.002</ArticleId><ArticleId IdType="pubmed">15519671</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman KW, Wu H, Sen S, Churchill GA. R/qtl: QTL mapping in experimental crosses. Bioinformatics. 2003;19(7):889&#x2013;890. doi: 10.1093/bioinformatics/btg112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btg112</ArticleId><ArticleId IdType="pubmed">12724300</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman KW and Sen S. A Guide to QTL Mapping with R/qtl. Springer-Verlag, New York, 2009. ISBN 987-0-387-92124-2. 396 pp.</Citation></Reference><Reference><Citation>Sen S and Churchill GA. A statistical framework for quantitative trait mapping. Genetics 2001;159:371&#x2013;387. doi: 10.1093/genetics/159.1.371</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/159.1.371</ArticleId><ArticleId IdType="pmc">PMC1461799</ArticleId><ArticleId IdType="pubmed">11560912</ArticleId></ArticleIdList></Reference><Reference><Citation>Doerge RW and Churchill GA. Permutation tests for multiple loci affecting a quantitative character. Genetics 1996;142(1):285&#x2013;294. doi: 10.1093/genetics/142.1.285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/142.1.285</ArticleId><ArticleId IdType="pmc">PMC1206957</ArticleId><ArticleId IdType="pubmed">8770605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander E and Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nature Genetics. 1995;11:241&#x2013;247. doi: 10.1038/ng1195-241</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1195-241</ArticleId><ArticleId IdType="pubmed">7581446</ArticleId></ArticleIdList></Reference><Reference><Citation>Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al.. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10(2):1&#x2013;4. doi: 10.1093/gigascience/giab008</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giab008</ArticleId><ArticleId IdType="pmc">PMC7931819</ArticleId><ArticleId IdType="pubmed">33590861</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Sims GE, Murphy S, Miller JR and Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688. doi: 10.1371/journal.pone.0046688</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046688</ArticleId><ArticleId IdType="pmc">PMC3466303</ArticleId><ArticleId IdType="pubmed">23056405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzzenente B, Metodiev MD, Wredenberg A, Bratic A, Park CB, C&#xe1;mara Y, et al.. LRPPRC is necessary for polyadenylation and coordination of translation of mitochondrial mRNAs. EMBO J. 2012;31(2):443&#x2013;456. doi: 10.1038/emboj.2011.392</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.392</ArticleId><ArticleId IdType="pmc">PMC3261557</ArticleId><ArticleId IdType="pubmed">22045337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasarman F, Nishimura T, Antonicka H, Weraarpachai W, Shoubridge EA; LSFC Consortium. Tissue-specific responses to the LRPPRC founder mutation in French Canadian Leigh Syndrome. Hum Mol Genet. 2015;24(2):480&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275074</ArticleId><ArticleId IdType="pubmed">25214534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho DM, Artavanis-Tsakonas S, Louvi A. The Notch pathway in CNS homeostasis and neurodegeneration. Wiley Interdiscip Rev Dev Biol. 2020;9(1):e358. doi: 10.1002/wdev.358</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wdev.358</ArticleId><ArticleId IdType="pubmed">31502763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim HY, Paek WK, Park A, Young Park M, Ki CS, et al.. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration in association with CADASIL. Neurologist. 2012;18(2):92&#x2013;95. doi: 10.1097/NRL.0b013e318247bb2d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NRL.0b013e318247bb2d</ArticleId><ArticleId IdType="pubmed">22367839</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilliott AA, Abdelhady A, Sunderland KM, Farhan SMK, Abrahao A, Binns MA, et al.. Contribution of rare variant associations to neurodegenerative disease presentation. NPJ Genom Med. 2021;6(1):80. doi: 10.1038/s41525-021-00243-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-021-00243-3</ArticleId><ArticleId IdType="pmc">PMC8478934</ArticleId><ArticleId IdType="pubmed">34584092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers C, Idris J, Scott H, Rogers M, Lee YB, Gaunt J, et al.. FUS interacts with nuclear matrix-associated protein SAFB1. BMC Biol. 2015;13:111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689037</ArticleId><ArticleId IdType="pubmed">26694817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi A, Takanashi K. FUS interacts with nuclear matrix-associated protein SAFB1 as well as Matrin3 to regulate splicing and ligand-mediated transcription. Sci Rep. 2016;6:35195. doi: 10.1038/srep35195</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep35195</ArticleId><ArticleId IdType="pmc">PMC5059712</ArticleId><ArticleId IdType="pubmed">27731383</ArticleId></ArticleIdList></Reference><Reference><Citation>Amadou C, Kum&#xe1;novics A, Jones EP, Lambracht-Washington D, Yoshino M, Lindahl KF. The mouse major histocompatibility complex: some assembly required. Immunol Rev. 1999;167:211&#x2013;221. doi: 10.1111/j.1600-065x.1999.tb01394.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065x.1999.tb01394.x</ArticleId><ArticleId IdType="pubmed">10319263</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiina T, Blancher A, Inoko H, Kulski JK. Comparative genomics of the human, macaque and mouse major histocompatibility complex. Immunology. 2017;150(2):127&#x2013;138. doi: 10.1111/imm.12624</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12624</ArticleId><ArticleId IdType="pmc">PMC5214800</ArticleId><ArticleId IdType="pubmed">27395034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Bendotti C. Major Histocompatibility Complex I Expression by Motor Neurons and Its Implication in Amyotrophic Lateral Sclerosis. Front Neurol. 2016;7:89. doi: 10.3389/fneur.2016.00089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00089</ArticleId><ArticleId IdType="pmc">PMC4904147</ArticleId><ArticleId IdType="pubmed">27379008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarotto GB, Nardo G, Trolese MC, Fran&#xe7;a MC Jr, Bendotti C, Rodrigues de Oliveira AL. The Emerging Role of the Major Histocompatibility Complex Class I in Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2017;18(11):2298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5713268</ArticleId><ArticleId IdType="pubmed">29104236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura N, Fukuda H, Kato A, Hirose S. MARCH-II is a syntaxin-6-binding protein involved in endosomal trafficking. Mol Biol Cell. 2005;16(4):1696&#x2013;1710. doi: 10.1091/mbc.e04-03-0216</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e04-03-0216</ArticleId><ArticleId IdType="pmc">PMC1073653</ArticleId><ArticleId IdType="pubmed">15689499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z, Huett A, Kuballa P, Giallourakis C, Xavier RJ. DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact. Cell Signal. 2008;20(1):73&#x2013;82. doi: 10.1016/j.cellsig.2007.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2007.08.019</ArticleId><ArticleId IdType="pmc">PMC2257480</ArticleId><ArticleId IdType="pubmed">17980554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou M, Thorburn DR, Ryan MT, McKenzie M. Assembly of mitochondrial complex I and defects in disease. Biochim Biophys Acta. 2009;1793(1):78&#x2013;88. doi: 10.1016/j.bbamcr.2008.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2008.04.015</ArticleId><ArticleId IdType="pubmed">18501715</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyshkina T, Banisor I, Shugart YY, Leist TP, Kalman B. Genetic variants of Complex I in multiple sclerosis. J Neurol Sci. 2005;228(1):55&#x2013;64 doi: 10.1016/j.jns.2004.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2004.09.027</ArticleId><ArticleId IdType="pubmed">15607211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibuchi K, Fukaya M, Shinohara T, Hara Y, Shiroshima T, Sugawara T, et al.. The Vps52 subunit of the GARP and EARP complexes is a novel Arf6-interacting protein that negatively regulates neurite outgrowth of hippocampal neurons. Brain Res. 2020;1745:146905. doi: 10.1016/j.brainres.2020.146905</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2020.146905</ArticleId><ArticleId IdType="pubmed">32473257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankat-Buttgereit B and Tamp&#xe9; R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev. 2002;82(1):187&#x2013;204. doi: 10.1152/physrev.00025.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00025.2001</ArticleId><ArticleId IdType="pubmed">11773612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt SC, Li R, Adams N, Winuthayanon W, Hamilton KJ, Donoghue LJ, et al.. Negative elongation factor is essential for endometrial function. FASEB J. 2019;33(2):3010&#x2013;3023. doi: 10.1096/fj.201801752</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201801752</ArticleId><ArticleId IdType="pmc">PMC6338652</ArticleId><ArticleId IdType="pubmed">30332301</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer A, Sampath SC, Intrator A, Min A, Gertler TS, Surmeier DJ, et al.. Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron 2009;64:678&#x2013;691. doi: 10.1016/j.neuron.2009.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.11.019</ArticleId><ArticleId IdType="pmc">PMC2814156</ArticleId><ArticleId IdType="pubmed">20005824</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton M, Voss TC, Misteli T. Identification by high-throughput imaging of the histone methyltransferase EHMT2 as an epigenetic regulator of VEGFA alternative splicing. Nucleic Acids Res. 2014;42(22):13662&#x2013;13673. doi: 10.1093/nar/gku1226</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1226</ArticleId><ArticleId IdType="pmc">PMC4267647</ArticleId><ArticleId IdType="pubmed">25414343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al.. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34(4):383&#x2013;94. doi: 10.1038/ng1211</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1211</ArticleId><ArticleId IdType="pubmed">12847526</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Diab A, AlTalbishi A, Rosin B, Kanaan M, Kamal L, Swaroop A, et al.. The combination of whole-exome sequencing and clinical analysis allows better diagnosis of rare syndromic retinal dystrophies. Acta Ophthalmol. 2019;97(6):e877&#x2013;e886. doi: 10.1111/aos.14095</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.14095</ArticleId><ArticleId IdType="pubmed">30925032</ArticleId></ArticleIdList></Reference><Reference><Citation>Begliuomini C, Magli G, Di Rocco M, Santorelli FM, Cassandrini D, Nesti C, et al.. VARS2-linked mitochondrial encephalopathy: two case reports enlarging the clinical phenotype. BMC Med Genet. 2019;20(1):77. doi: 10.1186/s12881-019-0798-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12881-019-0798-7</ArticleId><ArticleId IdType="pmc">PMC6505124</ArticleId><ArticleId IdType="pubmed">31064326</ArticleId></ArticleIdList></Reference><Reference><Citation>Coster G, Goldberg M. The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. Nucleus. 2010;1(2):166&#x2013;178. doi: 10.4161/nucl.1.2.11176</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/nucl.1.2.11176</ArticleId><ArticleId IdType="pmc">PMC3030693</ArticleId><ArticleId IdType="pubmed">21326949</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433&#x2013;439. doi: 10.1038/35044005</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35044005</ArticleId><ArticleId IdType="pubmed">11100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Park T, Chen H, Kim HY. GPR110 (ADGRF1) mediates anti-inflammatory effects of N-docosahexaenoylethanolamine. J Neuroinflammation. 2019;16(1):225. doi: 10.1186/s12974-019-1621-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1621-2</ArticleId><ArticleId IdType="pmc">PMC6858791</ArticleId><ArticleId IdType="pubmed">31730008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Qin Q, Xing Y, Guo D, Di L, Jia J. AARS2 leukoencephalopathy: A new variant of mitochondrial encephalomyopathy. Mol Genet Genomic Med. 2019;7(4):e00582. doi: 10.1002/mgg3.582</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.582</ArticleId><ArticleId IdType="pmc">PMC6465728</ArticleId><ArticleId IdType="pubmed">30706699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott A, Oroz J, Zweckstetter M. Molecular basis of the interaction of Hsp90 with its co-chaperone Hop. Protein Sci. 2020;29(12):2422&#x2013;2432. doi: 10.1002/pro.3969</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3969</ArticleId><ArticleId IdType="pmc">PMC7679967</ArticleId><ArticleId IdType="pubmed">33040396</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren MS, Zerangue N, Woodford K, Roberts LM, Tate EH, Feng B, et al.. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res. 2009;59(6):404&#x2013;413. doi: 10.1016/j.phrs.2009.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2009.02.007</ArticleId><ArticleId IdType="pubmed">19429473</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo MG, Xue K, Liu J, McBride H, Tsang BK. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking. J Biol Chem. 2012;287(6):3963&#x2013;3975. doi: 10.1074/jbc.M111.314765</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.314765</ArticleId><ArticleId IdType="pmc">PMC3281727</ArticleId><ArticleId IdType="pubmed">22117079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gama V, Swahari V, Schafer J, Kole AJ, Evans A, Huang Y, et al.. The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells. Sci Signal. 2014;7(334):ra67. doi: 10.1126/scisignal.2005309</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2005309</ArticleId><ArticleId IdType="pmc">PMC4182917</ArticleId><ArticleId IdType="pubmed">25028717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Jones A, Joo HY, Zhou D, Cao Y, Chen S, et al.. USP49 deubiquitinates histone H2B and regulates cotranscriptional pre-mRNA splicing. Genes Dev. 2013;27(14):1581&#x2013;1595. doi: 10.1101/gad.211037.112</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.211037.112</ArticleId><ArticleId IdType="pmc">PMC3731547</ArticleId><ArticleId IdType="pubmed">23824326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M, Anderson AG, Konopka G. FOXP transcription factors in vertebrate brain development, function, and disorders. Wiley Interdiscip Rev Dev Biol. 2020;9(5):e375. doi: 10.1002/wdev.375</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wdev.375</ArticleId><ArticleId IdType="pmc">PMC8286808</ArticleId><ArticleId IdType="pubmed">31999079</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Liu FC, Hirokawa K, Takahashi H. Expression of Foxp4 in the developing and adult rat forebrain. J Neurosci Res. 2008;86(14):3106&#x2013;3116. doi: 10.1002/jnr.21770</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21770</ArticleId><ArticleId IdType="pubmed">18561326</ArticleId></ArticleIdList></Reference><Reference><Citation>Estruch SB, Graham SA, Quevedo M, Vino A, Dekkers DHW, Deriziotis P, et al.. Proteomic analysis of FOXP proteins reveals interactions between cortical transcription factors associated with neurodevelopmental disorders. Hum Mol Genet. 2018;27(7):1212&#x2013;1227. doi: 10.1093/hmg/ddy035</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy035</ArticleId><ArticleId IdType="pubmed">29365100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelham CJ, Pandya AN, Agrawal DK. Triggering receptor expressed on myeloid cells receptor family modulators: a patent review. Expert Opin Ther Pat. 2014;24(12):1383&#x2013;1395. doi: 10.1517/13543776.2014.977865</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543776.2014.977865</ArticleId><ArticleId IdType="pmc">PMC4596234</ArticleId><ArticleId IdType="pubmed">25363248</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Allen M, Burgess JD, Wang X, Strickland SL, Aryal S, et al.. A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer&#x2019;s disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimers Dement. 2017;13(6):663&#x2013;673. doi: 10.1016/j.jalz.2016.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.10.005</ArticleId><ArticleId IdType="pmc">PMC5462884</ArticleId><ArticleId IdType="pubmed">27939925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah MO, Sweet MJ, Mansell A, Kellie S, Kobe B. TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target. J Leukoc Biol. 2016;100(1):27&#x2013;45. doi: 10.1189/jlb.2RI1115-531R</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.2RI1115-531R</ArticleId><ArticleId IdType="pubmed">27162325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Kim JR, van Bruggen R, Park J. RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Mol Cells. 2018;41(9):818&#x2013;829. doi: 10.14348/molcells.2018.0243</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2018.0243</ArticleId><ArticleId IdType="pmc">PMC6182225</ArticleId><ArticleId IdType="pubmed">30157547</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al.. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17(5):664&#x2013;666. doi: 10.1038/nn.3688</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. The International Journal of Biochemistry &amp; Cell Biology. 2009;41(2):349&#x2013;69. doi: 10.1016/j.biocel.2008.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2008.09.027</ArticleId><ArticleId IdType="pubmed">18848899</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein R, Thu CA, Goodman KM, Wolcott HN, Bahna F, Mannepalli S, et al.. Molecular logic of neuronal self-recognition through protocadherin domain interactions. Cell. 2015;163(3):629&#x2013;642. doi: 10.1016/j.cell.2015.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.026</ArticleId><ArticleId IdType="pmc">PMC4624033</ArticleId><ArticleId IdType="pubmed">26478182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama T, Yagi T. The role and expression of the protocadherin-alpha clusters in the CNS. Curr Opin Neurobiol. 2006;16(3):336&#x2013;342. doi: 10.1016/j.conb.2006.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2006.05.003</ArticleId><ArticleId IdType="pubmed">16697637</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano K, Kaneko R, Izawa T, Kawaguchi M, Kitsukawa T, Yagi T. Single-neuron diversity generated by Protocadherin-&#x3b2; cluster in mouse central and peripheral nervous systems. Front Mol Neurosci. 2012;5:90. doi: 10.3389/fnmol.2012.00090</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2012.00090</ArticleId><ArticleId IdType="pmc">PMC3431597</ArticleId><ArticleId IdType="pubmed">22969705</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas S, Emond MR, Duy PQ, Hao le T, Beattie CE, Jontes JD. Protocadherin-18b interacts with Nap1 to control motor axon growth and arborization in zebrafish. Mol Biol Cell. 2014;25(5):633&#x2013;642. doi: 10.1091/mbc.E13-08-0475</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E13-08-0475</ArticleId><ArticleId IdType="pmc">PMC3937089</ArticleId><ArticleId IdType="pubmed">24371087</ArticleId></ArticleIdList></Reference><Reference><Citation>Remillard D, Savage NA, Kedves AT, Paulk J, Chen X, Garcia FJ, et al.. Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8. ACS Chem Biol. 2021;16(11):2185&#x2013;2192. doi: 10.1021/acschembio.1c00256</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.1c00256</ArticleId><ArticleId IdType="pubmed">34515462</ArticleId></ArticleIdList></Reference><Reference><Citation>De Conti L, Akinyi MV, Mendoza-Maldonado R, Romano M, Baralle M, Buratti E. TDP-43 affects splicing profiles and isoform production of genes involved in the apoptotic and mitotic cellular pathways. Nucleic Acids Res. 2015;43(18):8990&#x2013;9005. doi: 10.1093/nar/gkv814</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv814</ArticleId><ArticleId IdType="pmc">PMC4605304</ArticleId><ArticleId IdType="pubmed">26261209</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese A, Laur&#xe0; M, Casali C, Nishino I, Hayashi YK, Magri S, et al.. Altered TDP-43-dependent splicing in HSPB8-related distal hereditary motor neuropathy and myofibrillar myopathy. Eur J Neurol. 2018;25(1):154&#x2013;163. doi: 10.1111/ene.13478</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13478</ArticleId><ArticleId IdType="pubmed">29029362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Ma L, Wang N, Zhou R, Wu J, Xie X, et al.. Antioxidant Gene Signature Impacts the Immune Infiltration and Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma. Front Genet. 2021;12:721252. doi: 10.3389/fgene.2021.721252</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.721252</ArticleId><ArticleId IdType="pmc">PMC8416991</ArticleId><ArticleId IdType="pubmed">34490047</ArticleId></ArticleIdList></Reference><Reference><Citation>Duclot F, Kabbaj M. The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders. Front Behav Neurosci. 2017;11:35. doi: 10.3389/fnbeh.2017.00035</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5337695</ArticleId><ArticleId IdType="pubmed">28321184</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner M, Schneider HC, Lill R, Neupert W. Dissection of protein translocation across the mitochondrial outer and inner membranes. Cold Spring Harb Symp Quant Biol 1995;60:619&#x2013;627. doi: 10.1101/sqb.1995.060.01.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/sqb.1995.060.01.066</ArticleId><ArticleId IdType="pubmed">8824435</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider HC, Berthold J, Bauer MF, Dietmeier K, Guiard B, Brunner M, et al.. Mitochondrial Hsp70/MIM44 complex facilitates protein import. Nature 1994;371:768&#x2013;774. doi: 10.1038/371768a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/371768a0</ArticleId><ArticleId IdType="pubmed">7935837</ArticleId></ArticleIdList></Reference><Reference><Citation>De Mena L, Coto E, S&#xe1;nchez-Ferrero E, Ribacoba R, Guisasola LM, Salvador C, et al.. Mutational screening of the mortalin gene (HSPA9) in Parkinson&#x2019;s disease. J Neural Transm (Vienna). 2009;116(10):1289&#x2013;1293</Citation><ArticleIdList><ArticleId IdType="pubmed">19657588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaustio M, Nayebzadeh N, Hinttala R, Tapiainen T, &#xc5;str&#xf6;m P, Mamia K, et al.. Loss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction. J Allergy Clin Immunol. 2021;148(2):599&#x2013;611. doi: 10.1016/j.jaci.2020.12.656</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.12.656</ArticleId><ArticleId IdType="pubmed">33662367</ArticleId></ArticleIdList></Reference><Reference><Citation>Stritt S, Nurden P, Turro E, Greene D, Jansen SB, Westbury SK, et al.. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood. 2016;127(23):2903&#x2013;2914. doi: 10.1182/blood-2015-10-675629</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-10-675629</ArticleId><ArticleId IdType="pubmed">26912466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>